Kornimate/medical-research-clean huggingface dataset:
effects of chemotherapy on muscle mass and exercise performance in patients with oesophageal cancer.

Conditions: Oesophageal Adenocarcinoma

Summary: curative treatment for oesophageal cancer involves undertaking chemotherapy followed by an operation to remove the tumour. chemotherapy has several effects upon the body, including effects upon the systems that control the creation and breakdown of muscle. we aim to review these effects by recording changes in the amount of exercise patients are able to undertake after chemotherapy and reviewing changes in muscle mass.

we aim to review the effects of chemotherapy on skeletal muscle mass and cardio-respiratory performance in patients with oesophageal adenocarcinoma. all patients will be assessed by a consultant anaesthetist and a medical member of the research team before commencing chemotherapy and after finishing their course. these assessments include a nutritional assessment, performance status assessments, blood assays, dual energy x-ray absorptiometry (dexa) scans, cardio-pulmonary exercise (cpex) testing and a muscle biopsy.

Eligibility criteria:
inclusion criteria: * oesophageal cancer * multidisciplinary team decision to offer neoadjuvant chemotherapy prior to surgery exclusion criteria: * metastatic disease

Keywords: neoadjuvant chemotherapy oesophageal cancer cardiorespiratory performance
the effect of adaptogen elixir on sleep improvement

Conditions: Sleep Disorder; Anxiety Disorders

Summary: this study aims to examine the effectiveness of adaptogen elixir herbal drink in relieving emotions and improving sleep quality. participants will be randomly assigned to either the placebo group or the adaptogen elixir herbal drink group, with 25 participants in each group. on the day of the experiment (week 0), participants are required to collect blood and saliva samples, fill out questionnaires assessing sleep disorders and stress condition, and use a sleep monitoring system to track their sleep and autonomic nervous system conditions. subsequently, participants will be given the experimental samples and instructed to consume them continuously for 4 weeks following the instruction. follow-up assessments will be conducted in the 2nd and 4th weeks, participants are required to collect blood and saliva samples, fill out questionnaires assessing sleep disorders and stress condition, and use a sleep monitoring system to track their sleep and autonomic nervous system conditions.


Eligibility criteria:
inclusion criteria: * adults aged above 18 years old. * individuals experiencing insomnia issues (psqi \> 5) or high levels of anxiety (gad-7 \> 9). * no medication use or regular use of sleeping pills or antidepressants in the past month. * no ongoing mental illnesses. * no ongoing physical illnesses. * no other sleep disorders. * no circadian rhythm issues. * no consumption of sleep or stress-related supplements in the past month. exclusion criteria: * pregnant or breastfeeding women. * individuals with significant organic diseases such as organ transplants, epilepsy or seizures, liver or kidney diseases, malignant tumors, endocrine disorders, or a history of alcohol or substance use disorders. * individuals known to be allergic to any components of the product.

Keywords: adaptogen
clinical comparison of pain score of needleless jet injector and conventional needle injection for teeth extraction anesthesia (split mouth technique).

Conditions: Pain Score

Summary: dental anesthesia with needle injection cause fear and anxiety in patients about the dental procedures. therefore, less painful anesthesia alternatives like needleless anesthesia devices to reduce the negative sensation of pain and fear that is always associated with traditional local anesthesia needle injection. the jet injector with injex is a needleless injector system that injects the local anesthesia solution into the tissues through a pressure. this research aims to compare the pain score of jet injector with injex and traditional local anesthesia needle injection for teeth extraction. method: 50 patients visiting dow ojha hospital, who needs extraction of bilateral teeth will be included in this study. data collection approval will be taken from institutional review board (irb) of duhs. complete procedure, study purpose and pain scale will be explained to patients and they will be told that information will be utilized for only research purpose and after that permission will be taken from participants. after taking history, quadrants will be divided; one for local anesthesia by the jet injector with injex and one for traditional local anesthesia needle injection. after that local anesthesia with jet injector injex will be given to one side and traditional local anesthesia needle injection will be given to other site for teeth extraction. then principle investigator will examine the patient pain through the pain scale (visual analog scale) of this study and supervisor will confirm it.


Eligibility criteria:
inclusion criteria: * 18-24 years old patient * patients having permanent dentition who require bilateral anterior or premolar teeth extraction * orthodontic patients who requires bilateral extraction of premolars * patients who give informed consent to take part in study exclusion criteria: * patients with local anesthesia allergy * patients with localized inflammation/ localized abscess/tenderness at site of injection * patients who do not give informed consent to take part in study

Keywords: pain score
correlation between trachebroncho malacia/hyperdynamic airway collapse and obstructive sleep apnea

Conditions: Trachebronchomalacia (TBM); Hyper Dynamic Airway Collapse (HDAC); Obstructive Sleep Apnea (OSA)

Summary: the investigators hypothesize that there is a strong correlation between osa and tbm/hdac. our hypothesis is based on the similarities in mechanism (airway collapse), symptoms (daytime and nocturnal dyspnea) predisposing conditions (obesity and neuromuscular abnormalities of the chest wall and the diaphragm), and effect of interventions (cpap and bipap) in these diseases.

tracheobronchomalacia (tbm) and hyperdynamic airway collapse (hdac) are two distinct airway diseases that lead to airway collapse which can in turn lead to the symptoms of dyspnea, cough, and inability to expectorate sputum effectively. tbm entails flaccid tracheal and bronchial cartilages leading to airway collapse, emanating primarily from the anterior wall of the lumen. it is seen in conditions such as relapsing polychondritis and saber sheath tracheal deformity. hdac on the other hand is the hyper-flaccidity of the membranous portion of the tracheobronchial tree leading to airway collapse. this condition is commonly seen with obesity and severe emphysema. tbm and hdac frequently coexist. in patients with tbm/hdac sleep disorders are common. patients often complain of poor quality sleep, snoring, daytime fatigue, and somnolence. these patients are often diagnosed with obstructive sleep apnea (osa) upon workup.

Eligibility criteria:
inclusion criteria: * females and males ages 18-80 years old * able and willing to provide written informed consent * existing diagnosis of tbm or hdac or both * no pre-existing diagnosis of osa * no history of reconstructive surgery of chest wall or diaphragm exclusion criteria: * inability to provide informed consent * non-english speaking * poorly controlled congestive heart failure * untreated insomnia * severe coronary artery disease with active symptoms of angina * patient is pregnant, or plans to become pregnant in next 3 months * moderate to severe bronchiectasis * severe untreated gastroesophageal disease (gerd). * moderate to large hiatal hernia deemed to be atleast in part responsible for tbm/hdac * airway obstruction not caused by tbm /hdac or secondary tbm/hdac caused by conditions such as chronic obstructive pulmonary disease (copd). * active or recent (with in last one year) cancer or cancer therapy (chemotherapy, radiation therapy or surgery) * inability to properly perform the home sleep test * unreliable test data after 2 attempts * bmi\>45

Keywords: tracheobronchomalacia tbm hyperdynamic airway collapse hdac obstructive sleep apnea osa
klebsiella pneumoniae necrotizing fasciitis: clinical and microbiological features

Conditions: Necrotizing Fasciitis

Summary: this is a retrospective descriptive study on the clinical and microbiological features of klebsiella pneumoniae necrotizing fasciitis.

background. necrotizing fasciitis is a rapidly progressive, life-threatening infectious disease that primarily involves soft tissue. traditionally, group a streptococcus is the major cause of this disease. in recent years, however, there are increasing case reports of necrotizing fasciitis solely caused by klebsiella pneumoniae. there are limited data regarding clinical and microbiological features of k. pneumoniae strains causing this disease. methods. we plan to review the medical records of necrotizing fasciitis cases treated during 1997-2010 at national taiwan university hospital, and compare the clinical features of cases caused by k. pneumonia and cases caused by group a streptococcus. we also plan to retrospectively identify necrotizing fasciitis-associated k. pneumoniae strains stored at -80oc at national taiwan university hospital, and perform virulence-associated hypermucoviscosity phenotyping, wzy (maga locus) and rmpa genotyping, and detection of 20-kb kfu/pts genomic region and other iron-uptake systems. expected results. this study is expected to yield the following important information: (1) the prevalence of monomicrobial k. pneumoniae necrotizing fasciitis cases among all necrotizing fasciitis cases at our hospital during the study period; (2) the distinct clinical features of k. pneumoniae necrotizing fasciitis, using group a streptococcal necrotizing fasciitis as the comparison group; (3) the microbiologic characteristics of k. pneumoniae strains causing monomicrobial necrotizing fasciitis, including hypermucoviscosity phenotype, wzy (maga locus) and rmpa genotype, and the presence of iron-uptake systems.

Eligibility criteria:
inclusion criteria: * definitive diagnosis of necrotizing fasciitis depends on intra-operative findings characterized by a lack of resistance to blunt dissection of the normally adherent fascia, presence of necrotic fascia, and purulent malodorous discharge. pathological findings of the involved fascia typically show neutrophils and bacterial clumps infiltrating between collagen bundles of with focal necrosis. exclusion criteria: * none

Keywords: necrotizing fasciitis, klebsiella pneumoniae
rosuvastatin/ezetimibe versus rosuvastatin in ascvd patients with type 2 dm

Conditions: Atherosclerotic Cardiovascular Disease; Type 2 Diabetes Mellitus

Summary: this study will evaluate the efficacy and aafety of rosuvastatin/ezetimibe combination therapy vs. rosuvastatin monotherapy in atherosclerotic cardiovascular disease patients with type 2 diabetes mellitus


Eligibility criteria:
inclusion criteria: 1. aged 19 and above 2. patient with type 2 diabetes taking oral diabetes medication for at least 3 months 3. patient diagnosed with ascvd * myocardial infarction (mi) * acute coronary syndrome (acs) * history of coronary revascularization(percutaneous coronary intervention, pci) * history of coronary artery bypass graft surgery (cabg) or other arterial revascularization procedures * stroke or transient ischemic attack (tia) * peripheral arterial disease (pad) * stable angina 4. written informed consent exclusion criteria: 1. type 1 diabetes 2. hba1c \> 8.5% at screening 3. fasting triglyceride ≥ 400 mg/dl at screening 4. history of muscular disease or rhabdomyolysis due to use of statin 5. hypersensitive to rosuvastatin or ezetemibe 6. contraindications stated in the spc of rosuvastatin or rosuvastatin/ezetimibe including the following: ① severe renal disease (crcl \< 30ml/min: cockcroft-gault formula or estimated gfr (mdrd) \< 30ml/min/1.73m2) ② alt, ast \> 3x uln or history of active liver disease ③ cpk \> 3x uln 7. those participating in clinical trials of other drugs 8. other than the above who is deemed to be ineligible to participate in the trial by investigator
accurate study for subjects with dry eyes

Conditions: Dry Eye Syndromes

Summary: to determine treatment and imaging outcomes in bilateral ocular surface disease management with an intracanalicular dexamethasone (0.4 mg) insert compared to standard topical over-the-counter artificial tears lubrication management

this study will evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert and patient administered artificial tears prn compared to patient administered artificial tears prn (control) in patients with bilateral ocular surface dry eye disease. the study is a self-controlled design and includes multiple objective, measureable, and quantifiable endpoints to best determine an objective response to treatment in patient eyes randomized to either the insert plus prn artificial tears or artificial tears prn control. to aid in ensuring best possible masking, dextenza is best visualized with blue light and yellow filter and therefore visualization will not be assessed until final visit following all measures.

Eligibility criteria:
inclusion criteria:a patient's study eye must meet the following criteria to be eligible for inclusion in the study: * age 18 years and older * demonstrate objective signs of ocular surface disease (osd) or * demonstrate symptoms of osd determined by a standardized questionnaire * no other corneal pathology to create unknown variability exclusion criteria:a patient who meets any of the following criteria in either eye will be excluded from the study: * history of using topical steroids or other anti-inflammatory drops within 6 months of the study * history of corticosteroid implant (ozurdex or iluvien) or intravitreal steroid use for macular disease in last 12 months * history or current use of oral steroids or immunosuppressants * active ocular infection * history of hsv * history corneal refractive surgery * uncontrolled glaucoma
study of hmb-enriched amino acid supplementation in patients with alcoholic liver disease and covid-19

Conditions: Alcoholic Liver Disease; COVID 19 Pneumonia

Summary: patients with covid-19 and comorbidities including alcohol associated liver disease (ald) are at risk for severe illness and abrupt or sudden clinical deterioration with ventilatory failure. â-hydroxy â-methyl butyrate (hmb), a non-nitrogenous leucine metabolite with anabolic properties, increases muscle mass and contractile function and enhances immune function. we aim to study the natural course of covid-19 in patients with ald and test whether hmb can affect ventilatory deterioration and improve short and long-term morbidity, mortality, and recovery from critical illness in symptomatic covid-19 patients with ald.


Eligibility criteria:
inclusion criteria: a. cases: patients with ald and covid-19 pneumonia: 1. clinical, imaging, laboratory, and/or histological diagnosis of alcoholic cirrhosis and/or alcoholic hepatitis 2. child pugh score 5-8, serum creatinine \<3, model for end stage liver disease score (meld) \<25 3. diagnosis of covid-19 pneumonia as defined by the who criteria: confirmed sars-cov-2 infection by pcr, evidence of bilateral pulmonary infiltrates on chest radiograph (cxr) or computed tomography (ct) and spo2 \<93% or on oxygen supplement 4. age of 21 years or older b. controls: patients without alcoholic liver disease (non-ald) and covid-19 pneumonia: 1. diagnosis of covid-19 pneumonia as defined by the who criteria: confirmed sars-cov-2 infection by pcr, evidence of bilateral pulmonary infiltrates on chest radiograph (cxr) or computed tomography (ct) and spo2 \<93% or on oxygen supplement 2. age of 21 years or older exclusion criteria: (both cases and controls) 1. patients requiring active ventilator support 2. anticoagulant/antiplatelet therapy (for those in the biopsy arm, see randomization schema. if clinically feasible, patients will be asked to hold their anticoagulants for the muscle biopsy after physician review), 3. recent gastrointestinal bleeding (\<3 months) 4. advanced organ diseases: congestive heart failure (nyha class 3 and 4), chronic obstructive pulmonary diseases (copd) (gold stage 3 and 4), chronic kidney disease (cr\>3), metastatic malignancy 5. medications that alter muscle protein metabolism except systemic corticosteroids 6. pregnancy 7. unwillingness/ inability to sign informed consent
open study to evaluate the safety of levocetirizine in young children (2 - 6 years) suffering from allergic rhinitis

Conditions: Allergic Rhinitis

Summary: 4 week open study to evaluate the safety of levocetirizine in young children (2 - 6 years) suffering from allergic rhinitis. as secondary objective, this study will assess the efficacy of the treatment by means of the t4ss (total 4 symptoms scores of allergic rhinitis) and each of the 4 individual rhinitis symptom scores


Eligibility criteria:
inclusion criteria: * at visit 1: * male or female outpatients aged 2 to 6 years old. * subjects suffering from allergic rhinitis (perennial and/or seasonal) and symptomatic as attested by the daily record card (drc). * at visit 2: * respected wash-out periods for the forbidden medication. exclusion criteria: * • presence of asthma requiring treatment by inhaled corticosteroids. * atopic dermatitis or urticaria requiring antihistamine treatment or the administration of oral or topical corticosteroids, or any other disease requiring the administration of oral or topical corticosteroids, immunomodulatory drugs, anti-inflammatory, or cytotoxic drugs. * use during the course of the study, or during the specific wash-out periods, of any of the following medications: intranasal or systemic corticosteroids (within 7 days), ketotifen (within 7 days), nedocromil or cromoglicate (within 7 days), loratadine and desloratadine (within 7 days), other antihistamines (within 3 days) or decongestants (per os, nasal spray, or drops - within 3 days), or any other concomitant medications that, in the opinion of the investigator, interfered with the study. * initiation or change of dose of an immunotherapy regimen during the course of the study.

Keywords: allergic rhinitis, safety, levocetirizine, children xyzal
do markers of systemic inflammatory response and tumor metabolism indicate radioresistance in head and neck cancer?

Conditions: Head and Neck Squamous Cell Carcinoma

Summary: the aim of the study is to prospectively evaluate whether markers of a patient's systemic inflammatory response in addition to fdg-pet/ct metabolic parameters of the primary tumor or of nodal metastases can predict radioresistance and survival before primary radiochemotherapy in advanced head and neck cancer patients.

this study prospectively investigates pretherapeutic markers of systemic inflammatory response (including neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, systemic inflammation response index, and systemic immune-inflammation) and fdg-pet/ct-derived metabolic parameters of tumor and nodal metastases (including maximum standardized uptake value, metabolic tumor volume, and total lesion glycolysis) and their potential prognostic value in head and neck cancer patients prior to primary radiochemotherapy.

Eligibility criteria:
inclusion criteria: * histopathologic diagnosis of squamous cell carcinoma of the head and neck * primary radio(chemo)therapy with curative intent * available pretherapeutic fdg-pet/ct imaging * available pretherapeutic differential blood analysis exclusion criteria: * other tumor entities of the head and neck including cutaneous squamous cell carcinoma * primary surgical treatment * ongoing infections or other inflammatory diseases at the time of diagnosis * patients not completing a course of irradiation with at least 66 gray locally
adv-tk therapy with surgery and chemoradiation for pancreas cancer (patk01)

Conditions: Pancreatic Adenocarcinoma; Pancreatic Cancer

Summary: the purpose of this phase 1 study is to evaluate the safety and potential efficacy of gene mediated cytotoxic immunotherapy for pancreatic cancer. the approach uses an adenoviral vector (disabled virus) engineered to express the herpes thymidine kinase gene (adv-tk), followed by an antiherpetic prodrug, valacyclovir.

the adv-tk vector is injected into the tumor or tumor bed at the time of biopsy or standard tumor surgery after which valacyclovir pills are taken for 14 days. two courses of adv-tk, each followed by valacyclovir, are given as adjuvant to standard of care therapies (surgery and/or chemoradiation) which have been shown to work cooperatively with adv-tk to kill tumor cells. arm a is for resectable tumors in which the first course is given prior to surgery and the second is at the time of surgery. arm b is for locally advanced disease in which both adv-tk injections are administered by needle injection into the tumor before and during chemoradiation. the hypothesis is that this combination therapy can be safely delivered and will lead to improvement in the clinical outcome for patients with pancreatic cancer.

Eligibility criteria:
inclusion criteria: * must have presumed pancreatic adenocarcinoma based on clinical and radiologic evaluation with identifiable tumor accessible for injection (pathologic diagnosis of pancreatic adenocarcinoma must be made prior to adv-tk injection * for arm a, resectable disease. arm b for locally advanced disease has completed accrual. * performance status must be ecog 0-2 * sgot (ast)\<3x upper limit of normal * serum creatinine\ 10ml/min * platelets\>100,000/mm3 and wbc\>3000/mm3 and anc\>1500/mm3 * must give study specific informed consent prior to enrollment exclusion criteria: * primary hepatic dysfunction including active hepatitis but not to exclude patients due to obstructive jaundice. if obstructive jaundice is clinically significant, bilirubin should be stable or decreasing prior to enrollment. * evidence of clinically significant pancreatitis as determined by the investigator. * patients on corticosteroids or other immunosuppressive drugs * known hiv+ patients * patients with acute infections (viral, bacterial or fungal infections requiring therapy) * pregnant or breast-feeding patients. female patients of childbearing age must have negative serum or urine pregnancy test within 1 week of beginning therapy * evidence of distant metastatic disease at the time of enrollment or other malignancy (except squamous or basal cell skin cancers) and no prior abdominal radiation therapy or prior treatment for pancreatic cancer * other serious co-morbid illness or compromised organ function

Keywords: immunotherapy gene therapy cytotoxicity tumor vaccine radiation surgery chemoradiation
does alkalinization reduce perceived pain levels during sentinel lymph node imaging?

Conditions: Pain

Summary: pain during nuclear medicine breast lymphnode detection procedures has been reported as high as 8.8/10. using sodium bicarbonate to alkalinize the radio-pharmaceutical injection, pain can safely be reduced from 6.6/10 to 4.7/10, during breast lymph node detection procedures. in sites other then the breast, using bicarbonate to make the injection's ph closer to natural, attempts to lower the pain levels will be performed. hypothesis: the perceived pain level during non breast sentinel lymph node techniques can be reduced by raising the ph of the injectate (tc-99m sc) to near the physiologic level of ph 7.40.


Eligibility criteria:
inclusion criteria: * patients presenting for sln imaging for melanoma or who have had an excisional biopsy for melanoma of the thorax and appendicular structures; * patients scheduled to receive two or more injections of tc-99m sc for the purpose of clinical management of melanoma or who have had an excisional biopsy for melanoma of the thorax and appendicular structures. exclusion criteria: * patients presenting for sln imaging of lesions involving the breast, ear, nose, and genitourinary regions; * patients scheduled to receive only a single injection of tc-99m sc; * pregnant or breast feeding women.

Keywords: pain alkalinization technetium 99m sulfur colloid sentinel lymphoscintigraphy?